CANNABINOID 1 RECEPTOR BLOCKADE DIMINISHES OBESITY AND DYSLIPIDEMIA VIA PERIPHERAL ACTIVATION OF BROWN ADIPOSE TISSUE
暂无分享,去创建一个
O. Meijer | L. Havekes | J. F. Berbée | J. Tamsma | B. Guigas | H. Sips | L. Pelgrom | J. Wouter | A. M. Hoek | A. Dam | C. Visseren | Robin C. Aggele | Marc Lombès | J. F. Berbée | A. Hoek
[1] W. D. van Marken Lichtenbelt,et al. Brown adipose tissue volume in healthy lean south Asian adults compared with white Caucasians: a prospective, case-controlled observational study. , 2014, The lancet. Diabetes & endocrinology.
[2] F. Villarroya,et al. BMP8B Increases Brown Adipose Tissue Thermogenesis through Both Central and Peripheral Actions , 2012, Cell.
[3] L. Havekes,et al. Estimation of Activity Related Energy Expenditure and Resting Metabolic Rate in Freely Moving Mice from Indirect Calorimetry Data , 2012, PloS one.
[4] D. Hardie,et al. AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.
[5] A. Efeyan,et al. Pten positively regulates brown adipose function, energy expenditure, and longevity. , 2012, Cell metabolism.
[6] Sang Geon Kim,et al. Rimonabant, a Cannabinoid Receptor Type 1 Inverse Agonist, Inhibits Hepatocyte Lipogenesis by Activating Liver Kinase B1 and AMP-Activated Protein Kinase Axis Downstream of Gαi/o Inhibition , 2011, Molecular Pharmacology.
[7] T. Hankemeier,et al. Plasma and Liver Lipidomics Response to an Intervention of Rimonabant in ApoE*3Leiden.CETP Transgenic Mice , 2011, PloS one.
[8] Oliver T. Bruns,et al. Brown adipose tissue activity controls triglyceride clearance , 2011, Nature Medicine.
[9] R. Zimmermann,et al. Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats. , 2010, European journal of pharmacology.
[10] S. Ambudkar,et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. , 2010, The Journal of clinical investigation.
[11] J. Orava,et al. Functional brown adipose tissue in healthy adults. , 2009, The New England journal of medicine.
[12] W. D. van Marken Lichtenbelt,et al. Cold-activated brown adipose tissue in healthy men. , 2009, The New England journal of medicine.
[13] E. Palmer,et al. Identification and importance of brown adipose tissue in adult humans. , 2009, The New England journal of medicine.
[14] N. Tennagels,et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle , 2009, Diabetologia.
[15] B. Oldfield,et al. The Effects of Rimonabant on Brown Adipose Tissue in Rat: Implications for Energy Expenditure , 2009, Obesity.
[16] C. Kahn,et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure , 2008, Nature.
[17] G. Marsicano,et al. Cannabinoid Type 1 Receptor Blockade Promotes Mitochondrial Biogenesis Through Endothelial Nitric Oxide Synthase Expression in White Adipocytes , 2008, Diabetes.
[18] J. Jukema,et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. , 2008, Atherosclerosis.
[19] P. Soubrié,et al. Rimonabant reduces obesity‐associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats , 2007, Hepatology.
[20] M. Fasshauer,et al. Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity , 2006, Diabetes.
[21] J. Jukema,et al. Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[22] F Xavier Pi-Sunyer,et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.
[23] D. Cota,et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.
[24] J. Després,et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.
[25] Arya M. Sharma,et al. Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.
[26] P. Soubrié,et al. The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] K. Mackie,et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.
[28] A. Rissanen,et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.
[29] P. Soubrié,et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.
[30] L. Petrocellis,et al. The endocannabinoid system: a general view and latest additions , 2004, British journal of pharmacology.
[31] D. Piomelli. The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.
[32] C. Flachskamm,et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.
[33] P. Soubrié,et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.
[34] M. Herkenham,et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.
[35] T. V. van Berkel,et al. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. , 2001, Journal of lipid research.
[36] F. Walker,et al. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. , 1998, The Journal of clinical investigation.
[37] J. K. Kruijt,et al. Selective liver targeting of antivirals by recombinant chylomicrons — a new therapeutic approach to hepatitis B , 1995, Nature Medicine.
[38] J. Brunzell,et al. Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. , 1993, Journal of lipid research.
[39] I. Feurer,et al. Bedside measurement of resting energy expenditure and respiratory quotient via indirect calorimetry , 1986 .
[40] C. E. West,et al. Separation of plasma lipoproteins by density-gradient ultracentrifugation. , 1975, Analytical biochemistry.
[41] W. J. Dyer,et al. A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.
[42] Sandra M. Sanabria-Bohórquez,et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. , 2008, Cell metabolism.